Oxaliplatin clinical activity: A review

Critical Reviews in Oncology/Hematology

Volumn 35, Issue 2, 2000, Pages 75-93

  Misset, Jean Louis ^a   Bleiberg, Harry ^b   Sutherland, William ^c   Bekradda, Mohamed ^c   Cvitkovic, Esteban ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b JULES BORDET INSTITUTE   (Belgium)

^c NONE

Author keywords

Other cancers; Ovarian cancer; Previously treated CRC; Untreated CRC

Indexed keywords

CISPLATIN; CISPLATIN DERIVATIVE; CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; RALTITREXED;

ADVANCED CANCER; BLOOD TOXICITY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CROSS RESISTANCE; DRUG INFUSION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; DYSESTHESIA; GERM CELL TUMOR; HUMAN; LUNG CARCINOMA; MALIGNANT MESOTHELIOMA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CARCINOMA; REVIEW; SOLID TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DNA ADDUCTS; DRUG RESISTANCE; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 0033908442     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00070-6     Document Type: Review

References (113)

1. Ozols R.F., Williams S. Testicular cancer. Curr. Probl. Cancer. 13:1989;285-335.
2. Loehrer P.J., Einhorn L. Drugs five years later: Cisplatin. Ann. Intern. Med. 100:1984;704-713.
3. Ozols R.F. Ovarian cancer. Curr. Probl. Cancer. 16:1992;61-126.
4. Kavanagh J., Tresukosol D., Edwards C. et al. Carboplatin reintroduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J. Clin. Oncol. 13:1995;1584-1588.
5. Nichols C.R., Williams S., Loehrer P.J. et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a southestern cancer study group and southwest oncology group protocol. J. Clin. Oncol. 9:1991;1163-1172.
6. Muggia F.M. Dose intensity: not the only path to clinical dose optimization [editorial]. J. Infus. Chemother. 6:1996;57-58.
7. Tashiro T., Kawada Y., Sakurai Y., Kidani Y. Antitumoral activity of a new platinum complex oxalato (trans-1,2-diaminocyclohexane) platinum (II): new experimental data. Biomed. Pharmacother. 43:1989;251-260.
8. Rixe O., Ortuzar W., Alvarez M. et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol. 52:1996;1855-1865.
9. Chollet P., Bensmaine A., Brienza S. et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann. Oncol. 7:1996;1065-1070.
10. Soulié P., Bensmaine A., Garrino C. et al. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur. J. Cancer. 33:1997;1400-1406.
11. Monnet I., Brienza S., Hugret F. et al. Phase II study of oxaliplatin in poor prognosis non-small cell lung cancer (NSCLC). Eur. J. Cancer. 34:1998;1124-1127.
12. Germann N., Brienza S., Rotarski M. et al. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann. Oncol. 10:1999;351-354.
13. Saris CP, Van de Vaart P, Blommaert FA, Rietbroek RC, Begg AC. DNA adduct formation in vitro and in platinum sensitive and resistant cells after treatment with lobaplatin, oxaliplatin and cisplatin. Seventh International Symposium on Platinum. Amsterdam O42, 1995 (abstract).
14. Faivre S, Raymond E, Chapman W, et al. Lesion in cellular DNA and apoptosis induced by oxaliplatin, Proc Am Assoc Cancer Res 1997 (abstract).
15. Daniel C., Fizazi K., Fandi A. et al. 'Tomudex' (Raltitrexed) and Eloxatine (Oxaliplatin) is an active combination with acceptable toxicity in malignant mesothelioma. Proc. Am. Soc. Clin. Oncol. (abstract). 18:1999;478a.
16. Schmidt W., Chaney S. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res. 53:1993;799-805.
17. Scheef E.D., Howell S. Computer modeling of the primary cisplatin and oxaliplatin DNA adducts and relevance to mismatch repair recognition. Proc. Annu. Meet. Am. Assoc. Cancer Res. (abstract). 39:1998;158.
18. Faivre S., Woynarowski J.M. Oxaliplatin effects on DNA integrity and apoptosis induction in human tumor cells. Proc. Annu. Meet. Am. Assoc. Cancer Res. (abstract). 39:1998;158.
19. Nehmé A., Baskaran R., Nebel S. et al. Introduction of JNK and c-ABI signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br. J. Cancer. 79:1999;1104-1110.
20. Gately D.P., Howell S. Cellular accumulation of the anticanceragent cisplatin: a review. Br. J. Cancer. 67:1993;1171-1176.
21. Perez R.P. Cellular and molecular determination of cisplatin resistance. Eur. J. Cancer. 34:1998;1535-1542.
22. Aebi S., Kurdihaidar B., Gordon R. et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 53:1996;3087-3090.
23. Aaltonen L., Peltomaki P., Leach F.S. et al. Clues to the pathogenesis of familial colorectal cancer. Science. 260:1999;812-816.
24. Thibodeau S.N., Bren G., Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 260:1993;816-819.
25. Chaney S., Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J. Natl. Cancer Inst. 88:1996;1346-1360.
26. Fink D., Nebel S., Aebi S. et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56:1996;4881-4886.
27. Fink D., Nebel S., Aebi S. et al. Effect of loss of DNA mismatch repair on cisplatin, oxaliplatin, and JM 216 sensitivity. Proc. Annu. Meet. Am. Assoc. Cancer Res. (abstract). 38:1997;523.
28. Fink D., Zheng H., Nebel S. et al. Resistance to cisplatin but not to oxaliplatin in DNA mismatch repair deficient xenografts in athymic nude mice. Proc. Am. Soc. Clin. Oncol. (abstract). 16:1997;531a.
29. Fink D., Nebel S., Norris P.S., Baergen R.N. et al. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int. J. Cancer. 77:1998;741-746.
30. Mathé G., Kidani Y., Triana K. et al. A phase I trial of trans-I-diaminocychlohexane oxalato-platinum (L-OHP). Biomed. Pharmacother. 40:1986;372-376.
31. Extra J.M., Espie M., Calvo F., Ferme C., Mignot L., Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol. 25:1990;299-303.
32. Caussanel J.P., Lévi F., Brienza S. et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J. Natl. Cancer Inst. 82:1990;1046-1050.
33. Nole E., Biganzoli L., Buzzoni R. et al. Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines. Eur. J. Cancer. 29:1993;1330-1331.
34. Asbury R., Kramer A., Green M. et al. A phase II study of carboplatin and CHIP in patients with metastatic colon carcinoma. Am. J. Clin. Oncol. 12:1989;416-419.
35. Perry D.J., Weiss R.B., Creekmore S.P., Micetich K., Curt G.A. Carboplatin for advanced colorectal carcinoma: a phase II study. Cancer Treat. Rep. 70:1986;301-302.
36. Pazdur R., Samson M., Baker L. CBDCA: phase II evaluation in advanced colorectal carcinoma. Am. J. Clin. Oncol. 10:1987;136-138.
37. Schmoll H., Gundersen S., Arnold A., Nys G., Gratton R., Canetta R. Phase II study of carboplatin in colorectal cancer. Ann. Oncol. (abstract). 1:1990;22.
38. Lokich J., Zipoli T., Greene R., Paul S., Sonnenborn H., Moore C. Protracted low-dose cisplatin infusion in advanced colorectal cancer. Cancer Treat. Rep. 70:1986;523-524.
39. Kovach J.S., Moertel C.G., Schutt A.J., Reitemeir R.G., Hahn R.G. Phase II study of cis-diamminedichloroplatinum (NSC 119875) in advanced carcinoma of the large bowel. Cancer Chemother. Rep. 57:1973;357-359.
40. Raymond E., Buquet-Fagot C., Djelloul S. et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anti-Cancer Drugs. 8:1997;876-885.
41. Raymond E., Lawrence R., Izbicka E., Faivre S., Von Hoff D. Activity of oxaliplatin against human tumor colony-forming units. Clin. Cancer Res. 4:1998;1021-1029.
42. Raymond E., Chaney S., Taamma A., Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol. 9:1998;1053-1071.
43. Becouarn Y., Ychou M., Ducreux M. et al. Phase II trial of oxaliplatin as first line chemotherapy in metastatic colorectal cancer patients. J. Clin. Oncol. 16:1998;2739-2744.
44. Diaz-Rubio E., Sastre J., Zaniboni A. et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann. Oncol. 9:1998;105-108.
45. Machover D., Diaz-Rubio E., De Gramont A. et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 7:1996;95-98.
46. Lévi F., Perpoint B., Garufi C. et al. Oxaliplatin activity against metastatic colorectal cancer: a phase II study of 5-day continuous venous infusion at circadian-rhythm modulated rate. Eur. J. Cancer. 29A:1993;1280-1284.
47. Bensmaine A., Marty M., De Gramont A. et al. Extended Access French Program (EAFP) of oxaliplatin (OXA)±5FU in 5-FU refractory advanced colorectal cancer (RACRC) patients (PTS). Proc. Am. Soc. Clin. Oncol. (abstract). 18:1999;253a.
48. Brienza S., Bensmaine A., Soulié P. et al. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU+/-FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC); Results from the European Compassionate-use program. Ann. Oncol. 10:1999;1311-1316.
49. Schmilovich A., Chacon R., Coppola F. et al. Expanded access program (EAP) single agent oxaliplatin (L-OHP) in fluoropyrimidine resistant advanced colorectal (FRAC) cancer patients (PTS). Proc. Am. Soc. Clin. Oncol. (abstract). 17:1998;272a.
50. De Gramont A., Gastiaburu C., Tournigand C. et al. Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 H infusion in pretreated metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (abstract). 13:1994;220.
51. De Gramont A., Vignoud J., Tournigand C. et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer. 33A:1997;214-219.
52. André T., Louvet C., Raymond E., Tournigand C., De Gramont A. A Bimonthly high-dose leucovorin,5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann. Oncol. 9:1998;1251-1253.
53. André T., Bensmaine A., Louvet C. et al. Multicenter phase II study of bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant for the same leucovorin regimen (FOLFOX 3/4). J. Clin. Oncol. 17:1999;3560-3568.
54. Maindrault-Goebel F., Louvet C., André T. et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 6). Eur. J. Cancer. 35:1999;1338-1342.
55. Maindrault-Goebel F., De Gramont A., Louvet C. et al. High-dose oxaliplatin with the simplified 48 h bimonthly leucovorin (LV) and 5-fluorouracil (5FU) regimen in pretreated metastatic colorectal cancer (FOLFOX). Proc. Am. Soc. Clin. Oncol. (abstract). 18:1999;265a.
56. De Gramont A., Maindrault-Goebel F., Louvet C. et al. Evaluation of oxaliplatin dose intensity with the bimonthly 48 h leucovorin (LV) and 5-fluorouracil (5FU) regimens (FOLFOX) in pretreated metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (abstract). 18:1999;265a.
57. Gerard B., Bleiberg H., Vandaele D. et al. Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective salvage therapy in patients with advanced colorectal cancer. Anti-Cancer Drugs. 9:1998;301-305.
58. Ardalan B., Chua L., Tian E. et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J. Clin. Oncol. 9:1991;625-630.
59. Buechele T., Schoeber C., Kroening H. et al. Weekly high-dose (HD) 5-fluorouracil (5-FU) and folinic acid (FA) with addition of oxaliplatin (L-OHP) after documented progression under high-dose infusional 5-FU/FA in patients (PTS) with advanced colorectal cancer (CRC): a preliminary report. Proc. Am. Soc. Clin. Oncol. (abstract). 17:1998;287a.
60. Gamelin E., Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer - status of the art. Crit. Rev. Oncol./Hematol. 30:1999;71-79.
61. Meyer V, Delva R, Gamelin E, et al. Oxaliplatin (LOHP) and 5-fluorouracil (5-FU) synergism in advanced colorectal cancer patients (ACRC), Eur J Cancer 1997;S167 (abstract).
62. Guérin-Meyer V., Delva R., Lortholary A. et al. Combination of Oxaliplatin (OXA)/5-FU/FA in 5-FU refractory advanced colorectal cancer (RACRC) patients treated with 5-FU/FA weekly PK guided regimen. Proc. Am. Soc. Clin. Oncol. (abstract). 18:1999;260a.
63. Van Cutsem E., Szanto J., Roth A. et al. Evalution of the addition of oxaliplatin (OXA) to the same mayo or German 5FU regimen in advanced refractory colorectal cancer (ARCRC). Proc. Am. Soc. Clin. Oncol. (abstract). 18:1999;234a.
64. Brienza S., Lévi F., Valori V.M. et al. Intensified (every 2 weeks) chronotherapy with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (L-OHP) in previously treated patients (pts) with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (abstract). 12:1993;197.
65. Bertheault-Cvitkovic F., Jami A., Itzhaki M. et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 14:1996;2950-2958.
66. ®) to the same leucovorin (LV) and 5-fluorouracil (5-FU) bimonthly regimens after progression in patients (pts) with metastatic colorectal cancer (MCRC): preliminary report. Proc. Am. Soc. Clin. Oncol. (abstract). 16:1997;270a.
67. André T., Louvet C., Raymond E., Tournigand C., De Gramont A. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann. Oncol. 9:1998;1251-1253.
68. Maindrault-Goebel F., De Gramont A., Louvet C. et al. Bi-monthly oxaliplatin with leucovorin (LV) and 5-fluorouracil (5FU) in pretreated matastatic colorectal cancer (FOLFOX6). Proc. Am. Soc. Clin. Oncol. (abstract). 17:1998;273a.
69. Bensmaine A., Marty M., De Gramont A. et al. Extended access french program (EAFP) of oxaliplatin (OXA)+5FU in 5-FU refractory advanced colorectal cancer (RACRC) patients (PTS). Proc. Am. Soc. Clin. Oncol. (abstract). 18:1999;253a.
70. Brienza S, Bekradda M, Bensmaine A, Tabah-Fisch I, Cvitkovic E. Overall clinical experience with oxaliplatin/5FU+FA synergy in pretreated advancedcolorectal cancer patients. Eighth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, 1999 (abstract).
71. Lévi F., Misset J., Brienza S. et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer. 69:1992;893-900.
72. Lévi F., Dogliotti L., Perpoint B. et al. A multicenter phase II trial of intensified chronotherapy with oxaliplatin (L-OHP), 5-Fluorouracil (5-FU) and folinioc acid (FA) in patients (PTS) with previouly untreated metastatic colorectal cancer (MCC). Proc. Am. Soc. Clin. Oncol. (abstract). 16:1997;266a.
73. Lévi F., Zidani R., Brienza S. et al. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. Cancer. 85:1999;2532-2540.
74. Lévi F., Zidani R., Vannetzel J.M. et al. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil and folinic acid (leucovorin) in patients with colorectal cancer metastases a randomized multi-institutional trial. J. Natl. Cancer Inst. 86:1994;1608-1617.
75. Lévi F., Zidani R., Misset J. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 350:1997;681-686.
76. Giacchetti S., Perpoint B., Zidani R. et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18:2000;136-147.
77. Giacchetti S., Brienza S., Focan C. et al. Contribution of second line oxaliplatin (OXA)-chronomodulated 5-fluorouracil-folinic acid (CM-5-FU-FA) and surgery to survival in metastic colorectal cancer patints (MCC PTS). Proc. Am. Soc. Clin. Oncol. (abstract). 17:1998;273a.
78. De Gramont A., Figer A., Seymour M. et al. A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol. (abstract). 17:1998;257.
79. De Gramont A., Bosset J.F., Milan C. et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a french intergroup study. J. Clin. Oncol. 15:1997;808-815.
80. Figer A., Louvet C., Homerin M. et al. Analysis of prognostic factors of overall survival (OS) in the randomized trial of bimonthly leucovorin and 5-fluorouracil regimen (LV5FU2) with or without oxaliplatin (OXA) in advanced colorectal cancer (ACC). Proc. Am. Soc. Clin. Oncol. (abstract). 18:1999;239a.
81. Seitz JF, Douillard JY, Paillot B, et al. Tomudex (raltitrexed) plus oxaliplatin as first-line chemotherapy in metastatic colorectal cancer (MCRC): A promising combination. Proc Am Soc Clin Oncol (abstract) 1999;18:257a.
82. Ducreux M., Fizazi K., Daniel C. et al. Updated results of a phase I trial of Tomudex (T) in combination with oxaliplatiin (L-OHP) in advanced solid tumors: A promising and active combination. Ann. Oncol. (abstract). 9:1998;125.
83. Wasserman E., Kalla S., Misset J. et al. Oxaliplatin (L-OHP) and irinotecan (CPT-11) phase I/II studies: results in 5-FU refractory (FR) colorectal cancer (CRC) patients (Pts). Proc. Am. Soc. Clin. Oncol. (abstract). 18:1999;238a.
84. Wasserman E., Cuvier C., Lokiec F. et al. Combination of oxaliplatin (L-OHP) plus irinotecan (CPT-11) in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J. Clin. Oncol. 17:1999;1751-1759.
85. Goldwasser F., Gross M., Tigaud J.M. et al. CPT-11/oxaliplatin (L-OHP) combination every two weeks: final results of a phase I study in advanced digestive malignancies. Proc. Am. Soc. Clin. Oncol. (abstract). 18:1999;176a.
86. Zeghari-Squalli N., Misset J., Cvitkovic E., Goldwasser F. Mechanism of the in vitro synergism between SN38 and oxaliplatin. Proc. Annu. Meet. Am. Assoc. Cancer Res. (abstract). 38:1997;3.
87. Scheithauer W, Kornek GV, Brugger S, et al. Randomized phase II study of irinotecan plus mitomycin C versus oxaliplatin plus mitomycin C previously treated patients with advanced colorectal cancer. EORTC-FFCD Joint meeting (June 23-26, 1999), Paris 145, 1999 (abstract).
88. Bismuth H., Adam R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin. Oncol. 25:1998;40-46.
89. Giacchetti S., Itzhaki M., Gruia G. et al. Long term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-Fluorouracil, leucovorin, oxaliplatin and surgery. Ann. Oncol. 10:1999;663-669.
90. Bismuth H., Adam R., Lévi F. et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg. 224:1996;509-522.
91. Pendyala L., Creaven P. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 53:1993;5970-5976.
92. Raymond E., Lawrence R., Izbicka E., Faivre S., Von Hoff D. Activity of oxaliplatin against human tumor colony-forming units. Clin. Cancer Res. 4:1998;1021-1029.
93. Mathé G., Kidani Y., Segiguchi M. et al. Oxalato-platinum or L-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother. 43:1989;237-250.
94. Rixe O, Antoine E, Benhammouda A, et al. Concomitant CPT-11 (c) and 5FU (f) combination: a phase I study. Anti-Cancer Treatment, Sixth International Congress 117, 1996.
95. Brown R., Hirst G.L., Gallagher W. et al. hMLH1 expression and cellular response of ovarian tumor cells to the treatment with cytotoxic anti-cancer agents. Oncogene. 15:1997;45-52.
96. Mackean M.J., Paul D. et al. The clinical relevance of mismatch repair protein immunohistochemistry in ovarian cancer. Proc. Am. Assoc. Cancer Res. (abstract). 30:1999;498.
97. Misset J., Kidani Y., Gastiaburu C. et al. Oxalatoplatinum (L-OHP): experimental and clinical studies. Howell S. Platinum and other metal coordination compounds in cancer chemotherapy. 1991;369-375 Plenum Press, New York.
98. Markman M., Hoskins W. Response to salvage chemotherapy in ovarian cancer: a critical need for precise definition of the treated population. J. Clin. Oncol. 10:1992;513-514.
99. Bougnoux P., Dieras V., Petit T. et al. A multicenter phase II study of oxaliplatin (OXA) as a single agent in platinum (PT) and/or taxanes (TX) pretreated advanced ovarian cancer (AOC) final results. Proc. Am. Soc. Clin. Oncol. (abstract). 18:1999;368a.
100. Piccart M., Green J., Lacave A.J. et al. Oxaliplaton or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J. Clin. Oncol. 18:2000;1193-1202.
101. Faivre S., Kalla S., Cvitkovic E. et al. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate use experience. Ann. Oncol. 10:1999;1125-1128.
102. Delaloge S., Laadem A., Chouaki N. et al. Feasability study of the paclitaxel (PXL), oxaliplatin (LOHP) and cisplatin (CDDP) combination in advanced ovarian cancer (AOC) patients (PTS). Proc. Am. Soc. Clin. Oncol. (abstract). 18:1999;365a.
103. Misset J., Chollet P., Vennin P. et al. Multicentric phase II-III trial of oxaliplatin (LOHP) versus cisplatin (P) both in association with cyclophosphamide (C) in the treatment of advanced ovarian cancer (AOC): toxicity and efficacy results. Proc. Am. Soc. Clin. Oncol. (abstract). 16:1997;354a.
104. de Cremoux H., Bekradda M., Monnet I. et al. Update of the oxaliplatin (L-OHP)/navelbine (NVB) phase I/II multicentric trial in patients (pts) with advanced non-small cell lung cancer. Ann. Oncol. (abstract). 9:1998;98.
105. Dunn T.A., Schmoll H., Grünwald V., Bokemeyer C., Casper J. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest. New Drugs. 15:1997;109-114.
106. Soulié P., Garrino C., Bensmaine A. et al. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ-cell cancer patients. J. Cancer Res. Clin. Oncol. 125:1999;707-711.
107. Ould Kaci M., Muracciole X., Vannetzel J.M. et al. Phase II randomized study of oxaliplatin (L-OHP), versus its combination with 5-FU in hormone refractory prostate cancer (HRPC) patients (pts). Proc. Annu. Meet. Am. Assoc. Cancer Res. (abstract). 40:1999;82.
108. Garufi C., Nistico C., Brienza S. et al. Oxaliplatin (L-OHP) activity in anthracycline (ANT)-resistant metastatic breast cancer (MBC) patients. Proc. Am. Soc. Clin. Oncol. (abstract). 16:1997;170a.
109. Degardin M., Cappelaere P., Krakowski I., Fargeot P., Cupissol D., Brienza S. Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur. J. Cancer B: Oral. Oncol. 32b:1996;278-279.
110. Maugard-Louboutin C., Fumoleau P., Ibrahim N. et al. Preliminary phase II trial of oxaliplatin (L-OHP) in malignant astrocytomas. Eur. J. Cancer (abstract). 29:1993;S191.
111. ®) to chronomodulated (CM) 5-fluorouracil (5-FU) and folinic acid (FA) for reversal of acquired chemoresistance in patients with advanced colorectal cancer (ACC). Proc. Am. Soc. Clin. Oncol. (abstract). 14:1995;192.
112. Louvet C., Bleiberg H., Gamelin E. et al. Oxaliplatin (L-OHP) synergistic clinical activity with 5-fluorouracil (FU) in FU-resistant colorectal cancer (CRC) patients (Pts) is independant of FU±FA schedule. Proc. Am. Soc. Clin. Oncol. (abstract). 15:1996;206.
113. Roca E., Carraro S., Chacon R. et al. Feasibility study of the combination oxaliplatin (I-OHP) plus 5-fluorouracil (Fu)-folinic (FA) acid in first-line advanced colorectal carcinoma. Proc. Am. Soc. Clin. Oncol. (abstract). 16:1997;304a.